{"id":49116,"date":"2018-06-05T10:30:46","date_gmt":"2018-06-05T14:30:46","guid":{"rendered":"https:\/\/asweetlife.org\/?p=49116"},"modified":"2018-06-07T17:12:13","modified_gmt":"2018-06-07T21:12:13","slug":"lilly-to-fund-sigilon-therapeutics-encapsulated-cell-research-to-treat-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=49116","title":{"rendered":"Lilly to Fund Sigilon Therapeutics’ Encapsulated Cell Research to Treat Type 1 Diabetes"},"content":{"rendered":"

April’s announcement that insulin maker Eli Lilly would invest up to $473 million in Sigilon Therapeutics and the cell encapsulation technology the Cambridge, Mass., biotech company is developing was big news in the type 1 diabetes space.\u00a0We\u2019ve been following this encapsulation technology<\/a>\u00a0since I met with Arturo Vegas in 2015, when he was a chemistry post doc at MIT working with Robert Langer and\u00a0 Daniel Anderson at the Koch Institute for Integrative Cancer Research. \u00a0(In the lab, Vegas and his colleagues tested almost 800 different versions of an alginate material, and found one in particular that seemed to work particularly well: the material protected beta cells in an immunocompetent mouse for the six months, the length of the study; and, when empty capsules made of the material were placed in the abdomen of a non-human primate, the monkey\u2019s immune system basically left them alone for more than 6 months, whereas capsules made of most\u00a0of the other materials they tested were soon encased in a fibrous gunk. In a more recent test, encapsulated beta cells remained clean after four months inside a primate.) Last year, Sigilon licensed the material from MIT for $23 million, but with the Lilly deal Sigilon will be specifically focused on developing and testing insulin-producing beta cells in the lab, and using the material, now named Afibromer, to protect them from type 1 diabetes\u2019 autoimmune attack. The goal of that product would be to replace the beta cells of someone with type 1\u2014meaning a patient could regulate their own blood sugar, without insulin injections.\u00a0 \u201cImagine how transformative this could be,\u201d says Vegas. \u201cI keep on coming back to that\u2014this will really change the way people with type 1 diabetes live.\u201d<\/p>\n

As Paul Wotton, Sigilon\u2019s CEO, explained it to me, his company will be managing the work until it gets to the point of filing an Investigational New Drug (IND) application with the FDA, at which point Lilly will take over, and design the testing of the product on real patients. Before the deal with Lilly, Sigilon was already working on developing the encapsulation technology to protect cells for patients with hemophilia (a disease that prevents blood from clotting), so the company will have established a timeline in terms of testing the material and going to the FDA for approval. \u201cIt\u2019s a good example, I think, of how creative corporate development can actually make things happen more quickly. We\u2019re using our skills; Lilly is using theirs. Without giving confidential information away, I do believe we\u2019ll be in the clinic within a few years\u2014that\u2019s what the current timeline is,\u201d says Wotton.<\/p>\n

Part of the work will involve translating induced pluripotent stem cells\u00a0 (iPS) into beta cells that can sense fluctuating glucose levels and respond.\u00a0 As Vegas points out, though, the steps to do this were outlined in 2014 (in a paper published in Cell<\/a> <\/em>\u00a0 by Douglas Melton, Felicia Pagliuca, Jeffrey Millman, Mads Gurtler and several other scientists).\u00a0<\/em>\u201cOnce the know-how is there, it\u2019s just about applying it,\u201d says Vegas. It\u2019s the encapsulation technology licensed from MIT that\u2019s \u201creally the advantage,\u201d says Wotton. \u201cNo one else has this ability to hide things from the immune system.\u201d The chemical modification that Vegas and his team discovered at MIT seems to have a profound effect on whether or not the immune system can detect what\u2019s encapsulated inside the material. \u00a0Wotton narrated two moving graphics for me, showing what happens when alginate beads are placed in mice; the beads in the first image were encapsulated in the material developed at MIT; the beads in the second image were not. \u201cWith the beads that are coated, using this technology, you can see macrophages swimming up to the surface, and they sort of sniff it and they turn around and go away. But if you use the same polymer without the chemistry from MIT on it, the macrophages will swim up and it\u00a0 will stick. And then, as soon as one of them is stuck, some of its friends show up, and all of a sudden there\u2019s a macrophage party going on at the implant. You don\u2019t see that with this chemistry.\u201d\u00a0<\/p>\n

As has been written here and elsewhere, creating a functional beta cell, encapsulated from the body\u2019s attack, is the holy grail of diabetes research. And that\u2019s part of the reason why this deal, involving a new encapsulation technology and a significant investment from an insulin manufacturer with its eye on the future, has received such attention. Both Vegas and Wotton emphasized to me the speed of this process, while acknowledging that progress can\u2019t come fast enough for those affected by type 1. \u201cThis takes time of course,\u201d says Vegas. \u201cBut this project was started in 2008; in scientific terms we are moving at breakneck speed.\u201d Wotton expressed a similar point of view: \u201cI know that if you\u2019re a patient with any dread disease, one day is too many days.\u00a0 But this is a rapid development, and everything just seems to be coming together now. We\u2019ve got this technology; we\u2019ve got the ability to convert these IPS cells into beta cells using a process that\u2019s quite well defined.\u00a0 And now we\u2019ve got to put it together and execute it.\u00a0 And we\u2019ve got the money and the focus to do it.”<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

…<\/p>\n","protected":false},"author":18,"featured_media":49151,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1445],"tags":[],"yoast_head":"\nLilly to Fund Sigilon Therapeutics' Encapsulated Cell Research to Treat Type 1 Diabetes<\/title>\n<meta name=\"description\" content=\"In April, insulin maker Eli Lilly announced it would invest up to $473 million in Sigilon Therapeutics and the cell encapsulation technology the Cambridge, Mass., biotech company is developing was big news in the type 1 diabetes space...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=49116\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Katie Bacon\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=49116\",\"url\":\"https:\/\/asweetlife.org\/?p=49116\",\"name\":\"Lilly to Fund Sigilon Therapeutics' Encapsulated Cell Research to Treat Type 1 Diabetes\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=49116#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=49116#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2018\/06\/sigilon-Katie-Bacon2.gif\",\"datePublished\":\"2018-06-05T14:30:46+00:00\",\"dateModified\":\"2018-06-07T21:12:13+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/d9db494b4a0cbf28744f6c4a9c73329e\"},\"description\":\"In April, insulin maker Eli Lilly announced it would invest up to $473 million in Sigilon Therapeutics and the cell encapsulation technology the Cambridge, Mass., biotech company is developing was big news in the type 1 diabetes space...\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=49116#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=49116\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=49116#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2018\/06\/sigilon-Katie-Bacon2.gif\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2018\/06\/sigilon-Katie-Bacon2.gif\",\"width\":640,\"height\":480},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=49116#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lilly to Fund Sigilon Therapeutics’ Encapsulated Cell Research to Treat Type 1 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/d9db494b4a0cbf28744f6c4a9c73329e\",\"name\":\"Katie Bacon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/8cc124bd5d3d2d03be80239ba09df7cc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/8cc124bd5d3d2d03be80239ba09df7cc?s=96&d=mm&r=g\",\"caption\":\"Katie Bacon\"},\"description\":\"Katie Bacon is a writer and editor based in Boston. Her daughter, Bisi, was diagnosed with type 1 diabetes in August, 2012, when she was six. Katie worked as an editor at The Atlantic, and her writing has appeared in The New York Times, The Boston Globe, and other publications. Katie and her husband, Mark, have two children\u2014Bisi and her older brother, Jamie.\",\"url\":\"https:\/\/asweetlife.org\/?author=18\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lilly to Fund Sigilon Therapeutics' Encapsulated Cell Research to Treat Type 1 Diabetes","description":"In April, insulin maker Eli Lilly announced it would invest up to $473 million in Sigilon Therapeutics and the cell encapsulation technology the Cambridge, Mass., biotech company is developing was big news in the type 1 diabetes space...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=49116","twitter_misc":{"Written by":"Katie Bacon","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=49116","url":"https:\/\/asweetlife.org\/?p=49116","name":"Lilly to Fund Sigilon Therapeutics' Encapsulated Cell Research to Treat Type 1 Diabetes","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=49116#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=49116#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2018\/06\/sigilon-Katie-Bacon2.gif","datePublished":"2018-06-05T14:30:46+00:00","dateModified":"2018-06-07T21:12:13+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/d9db494b4a0cbf28744f6c4a9c73329e"},"description":"In April, insulin maker Eli Lilly announced it would invest up to $473 million in Sigilon Therapeutics and the cell encapsulation technology the Cambridge, Mass., biotech company is developing was big news in the type 1 diabetes space...","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=49116#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=49116"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=49116#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2018\/06\/sigilon-Katie-Bacon2.gif","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2018\/06\/sigilon-Katie-Bacon2.gif","width":640,"height":480},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=49116#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Lilly to Fund Sigilon Therapeutics’ Encapsulated Cell Research to Treat Type 1 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/d9db494b4a0cbf28744f6c4a9c73329e","name":"Katie Bacon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/8cc124bd5d3d2d03be80239ba09df7cc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8cc124bd5d3d2d03be80239ba09df7cc?s=96&d=mm&r=g","caption":"Katie Bacon"},"description":"Katie Bacon is a writer and editor based in Boston. Her daughter, Bisi, was diagnosed with type 1 diabetes in August, 2012, when she was six. Katie worked as an editor at The Atlantic, and her writing has appeared in The New York Times, The Boston Globe, and other publications. Katie and her husband, Mark, have two children\u2014Bisi and her older brother, Jamie.","url":"https:\/\/asweetlife.org\/?author=18"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/49116"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49116"}],"version-history":[{"count":9,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/49116\/revisions"}],"predecessor-version":[{"id":49162,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/49116\/revisions\/49162"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/49151"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}